Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study

BACKGROUND: Malignancy risk with tumour necrosis factor inhibitor (TNFi) therapy remains unclear. Our primary aim was to assess malignancy risk with TNFi therapy in a cohort of Australian patients with rheumatoid arthritis (RA). We also assessed risk in a biologic-naïve group. METHODS: Demographic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchbinder, Rachelle, Van Doornum, Sharon, Staples, Margaret, Lassere, Marissa, March, Lyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615333/
https://www.ncbi.nlm.nih.gov/pubmed/26481039
http://dx.doi.org/10.1186/s12891-015-0772-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615333/
https://www.ncbi.nlm.nih.gov/pubmed/26481039
http://dx.doi.org/10.1186/s12891-015-0772-2

Ejemplares similares